Guillain-Barré syndrome after treatment with sunitinib malate?
Autor(es): Mulherin Brian.; Loconte Noelle K.; Holen Kyle D.
Resumo: Sunitinib malate (Sutent, SU011248) is an oral multitargeted tyrosine kinase inhibitor used for treatment of renal cell carcinoma and gastrointestinal stromal tumor. We report a case of a patient who developed Guillain-Barrd syndrome after initial treatment with sunitinib, with recurrent symptoms upon reintroducing the drug. This is the first report of such an effect. The literature on chemotherapy-induced Guillain-Barri syndrome is also reviewed. Oncology providers should be aware of this rare but potentially serious possible adverse effect of sunitinib.
Imprenta: Oncology, v. 22, n. 1, p. 66-67, 70-71, 2008
Descritores: Guillain-Barre Syndrome - Cell ; Guillain-Barre Syndrome - Pathogenesis ; Guillain-Barre Syndrome - Public health
Data de publicação: 2008